InvestorsHub Logo

TPX

Followers 0
Posts 40567
Boards Moderated 4
Alias Born 10/24/2013

TPX

Re: TPX post# 42978

Tuesday, 08/15/2017 9:40:56 AM

Tuesday, August 15, 2017 9:40:56 AM

Post# of 50649
As OXIS also Multicell makes progress!!! Look here >>>

USPTO Approves and Issues Patent for Oxis-4235 to Treat Multiple Myeloma

http://www.erienewsnow.com/story/35813976/uspto-approves-and-issues-patent-for-oxis-4235-to-treat-multiple-myeloma

Oxis Biotech Announces U.S. Patent and Trademark Office Notification of Patent Issuance for Oxis-4235 as Treatment for Multiple Myeloma

https://finance.yahoo.com/news/oxis-biotech-announces-u-patent-131500785.html

Its lead drug candidates include OXS-2175, a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer; OXS-4235, a small molecule therapeutic candidate to treat multiple myeloma and associated osteolytic lesion; and OXS-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors.

http://financeregistrar.com/oxis-international-inc-otcmktsoxis-moves-needle/